Wells Fargo analyst Larry Biegelsen notes that last week, a contentious hearing was held in the Northern District of California in the litigation where Nevro (NVRO) is asserting that Boston Scientific (BSX) infringes seven patents related to high-frequency stimulation. News coverage of the hearing has understandably focused on the fact that the judge expressed significant skepticism with respect to many of the Nevro patents and this news coverage has likely lead to a 15.1% drop in Nevro's share price on July 10, he adds. Biegelsen's patent consultant, however, believes Nevro is very likely to emerge in good shape, despite the headlines. The analyst reiterates a Market Perform rating on Nevro's shares.